{"entity":{"id":"nct04121455","kind":"trial","name":"Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients","aka":[],"tldr":"A phase 1/2 trial of Bevacizumab, Pembrolizumab and Temozolomide in glioma & glioblastoma, run by TME Pharma AG, active and no longer recruiting.","summary":"Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients is a phase 1/2 interventional study registered as NCT04121455 by TME Pharma AG, with 117 participants enrolled, started 2019-09-12 and due to reach its primary completion in 2028-12. Interventions recorded: Olaptesed pegol, Radiotherapy, Bevacizumab, Pembrolizumab and Temozolomide (TMZ).","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04121455","url":"https://clinicaltrials.gov/study/NCT04121455"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["bevacizumab","pembrolizumab","temozolomide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04121455","phase":"1/2","setting":"Single-arm, Dose-escalation Phase 1/2 Study of Olaptesed Pegol (NOX-A12) in Combination With Irradiation in Inoperable or Partially Resected First-line Glioblastoma Patients With Unmethylated MGMT Promoter With a Multiple-arm Expansion Group","sponsor":"TME Pharma AG","enrolled":117,"outcomes":[]},"route":"/trials/nct04121455/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}]}}